4-Methylmorpholine → HCID 86755342, compound
Reaction equation
[C:1]([O:5][C:6]([N:8]1[C:12]2[CH2:13][C@H:14]([C:30](O)=[O:31])[CH:15]([C:23]([O:25][C:26]([CH3:29])([CH3:28])[CH3:27])=[O:24])[N:16]([C:17]3[CH:22]=[CH:21][CH:20]=[CH:19][CH:18]=3)[C:11]=2[N:10]=[CH:9]1)=[O:7])([CH3:4])([CH3:3])[CH3:2].[C:33]([N:35]([CH2:43][C:44]1[CH:49]=[CH:48][CH:47]=[CH:46][CH:45]=1)[CH2:36][CH2:37][C:38]1[N:42]=CNC=1)#[N:34].C1C=CC2N(O)N=[N:56][C:54]=2C=1.[CH3:60]N1CCOCC1>CN(C=O)C.C(Cl)CCl>[C:1]([O:5][C:6]([N:8]1[C:12]2[CH2:13][C@H:14]([C:30](=[O:31])[NH:42][CH2:38][CH2:37][C:36]3[N:35]([CH2:43][C:44]4[CH:45]=[CH:46][C:47]([C:54]#[N:56])=[CH:48][CH:49]=4)[CH:33]=[N:34][CH:60]=3)[CH:15]([C:23]([O:25][C:26]([CH3:29])([CH3:27])[CH3:28])=[O:24])[N:16]([C:17]3[CH:22]=[CH:21][CH:20]=[CH:19][CH:18]=3)[C:11]=2[N:10]=[CH:9]1)=[O:7])([CH3:3])([CH3:4])[CH3:2]Participants
7
Procedure
To a solution of the product as described in Step A above, [4-phenyl-6,7-dihydro-4-H-imidazo[4,5]pyridine-1,5,6(S)-tricarboxylic acid 1,5-di-tert-butyl ester] (0.34 g, 0.826 mm), cyanobenzyl histamine (5)(0.187 g, 0.826 mm), HOBt (0.126 g, 0.826 mm), EDC (0.158 g, 0.826 mm) in DMF (5 ml) was added NMM (0.27 ml, 2.48 mm). The solvents were removed in vacuo and the residue was partitioned with EtOAc and saturated sodium bicarbonate. The EtOAc layer was dried with brine and magnesium sulfate. The EtOAc was removed in vacuo to obtain the title compound as a solid which was used in the next step as is.
Workup
- customThe solvents were removed in vacuo
- customthe residue was partitioned with EtOAc and saturated sodium bicarbonate
- dry with materialThe EtOAc layer was dried with brine and magnesium sulfate
- customThe EtOAc was removed in vacuo
Sources & evidence
- ORD record
- ord-999c44ef9f2f44ac86069c4bff7af531
- Source dataset
- uspto-grants-2000_04
- Patent number
- US06054466
Reaction notes
Loading…